Ferguson J E, Burkett B J, Pinkerton J V, Thiagarajah S, Flather M M, Martel M M, Hogge W A
Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville 22908.
Am J Obstet Gynecol. 1993 Aug;169(2 Pt 1):332-9; discussion 339-40. doi: 10.1016/0002-9378(93)90084-v.
Our purpose was to determine whether intraamniotic 15(s)-15-methyl prostaglandin F2 alpha could serve effectively and safely as a surrogate for natural prostaglandin F2 alpha when used to effect middle and late second-trimester pregnancy termination for genetic indications. Further, we sought to compare efficacy and side effects with those found when intravaginal prostaglandin E2 is used.
A total of 62 patients received intraamniotic 15(s)-15-methyl prostaglandin F2 alpha and urea, and intracervical laminaria. Case patients at < or = 20 weeks' gestation (n = 32) were compared with case patients at > 20 weeks (n = 30) and with a matched group (n = 64; 1:2 ratio) of control patients in whom cervical laminaria and intraamniotic urea were used with prostaglandin E2 vaginal suppositories.
The mean induction-to-abortion interval among the case patients (gestational age 16 to 27 weeks) was 13 hours 11 minutes; 60 of 62 (97%) were delivered within 24 hours. There was a statistically significant negative correlation between the induction-to-abortion interval and gestational age (p = 0.04). When patients at < or = 20 weeks and those at > 20 weeks were compared, few differences were noted. The mean induction-to-abortion interval for case patients at < or = 20 weeks was 13 hours 54 minutes versus 19 hours 34 minutes for control patients (p = 0.001). One of 32 (3%) case patients remained undelivered beyond 24 hours compared with 17 of 64 (27%) control patients (p < 0.01). Immediate and delayed complications were uncommon in either group.
Our study demonstrates that 15(s)-15-methyl prostaglandin F2 alpha can serve safely as a surrogate for prostaglandin F2 alpha when used in combination with urea and laminaria for termination of pregnancy. This technique appears safe for use through 27 weeks' gestation; further investigation is encouraged.
我们的目的是确定羊膜腔内注射15(S)-15-甲基前列腺素F2α在用于因遗传指征而终止妊娠中期和晚期妊娠时,能否有效且安全地替代天然前列腺素F2α。此外,我们试图将其疗效和副作用与使用阴道前列腺素E2时的情况进行比较。
共有62例患者接受了羊膜腔内注射15(S)-15-甲基前列腺素F2α和尿素,以及宫颈放置海藻棒。将妊娠≤20周的病例患者(n = 32)与妊娠>20周的病例患者(n = 30)进行比较,并与一组匹配的(n = 64;1:2比例)对照患者进行比较,对照患者使用海藻棒和羊膜腔内注射尿素并联合使用前列腺素E2阴道栓剂。
病例患者(孕周16至27周)的平均引产至流产间隔时间为13小时11分钟;62例中有60例(97%)在24小时内分娩。引产至流产间隔时间与孕周之间存在统计学显著的负相关(p = 0.04)。当比较妊娠≤20周的患者和>20周的患者时,未发现明显差异。妊娠≤20周的病例患者的平均引产至流产间隔时间为13小时54分钟,而对照患者为19小时34分钟(p = 0.001)。32例病例患者中有1例(3%)在24小时后仍未分娩,而64例对照患者中有17例(27%)(p < 0.01)。两组中即刻和延迟并发症均不常见。
我们的研究表明,15(S)-15-甲基前列腺素F2α与尿素和海藻棒联合用于终止妊娠时,可安全替代前列腺素F2α。该技术在妊娠27周前使用似乎是安全的;鼓励进一步研究。